IL-13 from Th2-type cells suppresses induction of antigen-specific Th1 immunity in a T-cell lymphoma

International Immunology

Volumn 22, Issue 1, 2009, Pages 53-63

  Deepak, Praveen ^a   Kumar, Sanjay ^a   Kishore, Dhiraj ^b   Acharya, Arbind ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

Dalton's lymphoma; DTH; IFN ; IL 13; MIP 1

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA2; 1 FLUORO 2,4 DINITROBENZENE; 1,5 DIFLUORO 2,4 DINITROBENZENE; 1,5-DIFLUORO-2,4-DINITROBENZENE; DRUG DERIVATIVE; GAMMA INTERFERON; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELL PROLIFERATION; CONTACT ALLERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; FEMALE; IMMUNE RESPONSE; IMMUNOREGULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T CELL LYMPHOMA; TH1 CELL; TH2 CELL; ADOPTIVE TRANSFER; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; CONTACT DERMATITIS; DRUG EFFECT; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; SECRETION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL3; DERMATITIS, CONTACT; DINITROFLUOROBENZENE; HYPERSENSITIVITY, DELAYED; INTERFERON-GAMMA; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; LYMPHOCYTE ACTIVATION; LYMPHOMA, T-CELL; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; TH1 CELLS; TH2 CELLS;

EID: 77949907464     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxp114     Document Type: Article

References (55)

1. Goldie, H. and Felix, M. D. 1951. Growth characteristics of free tumor cells transformed serially in the peritoneal fluid of mouse. Cancer Res. 11:73.
2. Parajuli, P., Singh, S. M., Kumar, A. and Sodhi, A. 1997. Alterations in the tumoricidal functions of murine tumor-associated macrophages during progressive growth of a tumor in vivo. Cancer J. 10:222.
3. Pawlec, G., Zeuthen, J. and Kiessling, R. 1997. Escape from host anti-tumor immunity. Crit. Rev. Oncog. 8:111.
4. Chouaib, S., Asselin, P. G., Mami, C. F., Caignard, A. and Blay, J. Y. 1997. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today 18:493.
5. Sulitzeanu, D. 1993. Immunosuppressive factors in human cancer. Adv. Cancer Res. 60:247.
6. Oppenheim, J. and Fujiwara, H. 1996. The role of cytokines in cancer. Cytokine Growth Factor Rev. 7:279.
7. Morisaki, T., Katano, M., Ikubo, A. et al. 1996. Immunosuppressive cytokines (IL-10, TGF-β) genes expression in human gastric carcinoma tissue. J. Surg. Oncol. 63:234.
8. Spellman, J. E., Gollnick, S. O., Zhang, P. J. and Tomasi, T. B. 1996. Cytokine production by human soft tissue sarcomas: implications for immunosuppression within the tumor bed. Surg. Oncol. 5:237.
9. Venetsanakos, E., Beckman, I., Bradley, J. and Skinner, J. M. 1997. High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumors. Br. J. Cancer 75:1826.
10. Romagnani, S. 1994. Lymphokine production by human T cells in disease states. Annu. Rev. Immunol. 12:227.
11. Terabe, M., Matsui, S., Noben-Trauth, N. et al. 2000. NKT cell mediated repression of tumor immunosurveillance by IL-13 and the IL-4-STAT-6 pathway. Nat. Immunol. 1:515.
12. Terabe, M., Matsui, S., Park, J. M. et al. 2003. Transforming growth factor-b production and myeloid cells are an effector mechanism through which CD1d-restricted T-cells block cytotoxic T-lymphocyte-mediated tumor immune surveillance: abrogation prevents tumor reoccurrence. J. Exp. Med. 198:1741.
13. Zurawski, S. M., Vega, F. Jr., Hugghe, B. and Zurawski, G. 1993. Receptors for IL-13 and IL-4 are complex and share a novel component that functions in signal transduction. EMBO J. 12:2663.
14. Punnonen, J., Aversa, G., Cocks, B. G. et al. 1993. Interleukin-13 induces interleukin-4-independent IgG4 and IgE synthesis and CD23 expression by human B-cell. Proc. Natl Acad. Sci. USA 90:3730.
15. Doherty, T. M., Kastelein, K., Menon, S., Andrade, S. and Coffman, R. L. 1993. Modulation of murine macrophages function by IL-13. J. Immunol. 151:7151.
16. de Waal Malefyt, R., Figdor, C., Hujibens, R. et al. 1993. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. J. Immunol. 151:6370.
17. Bogdan, C., Thuring, H., Dlaska, M., Rollinghoff, M. and Weiss, G. 1997. Mechanism of suppression of macrophage nitric oxide release by IL-13: influence of the macrophages population. J. Immunol. 159:4506.
18. Doyle, A. G., Herbein, G., Montaner, L. J. et al. 1994. Interleukin-13 alters the activation state of murine macrophages in vitro: comparison with interleukin-4 and interferon-gamma. Eur. J. Immunol. 24:1441.
19. Cocks, B. G., de Waal Malefyt, R., Galizzi, J. P., de Vries, J. E. and Aversa, G. 1993. Interleukin-13 induces proliferation and differentiation of human B-cells activated by the CD40 ligand. Int. Immunol. 5:657.
20. Deepak, P., Kumar, S. and Acharya, A. 2008. Gender dichotomy in antibody response in a T cell lymphoma: involvement of IL-13 and gonadal hormones. Am. J. Reprod. Immunol. 59:127.
21. McKenzie, A. N. 2000. Regulation of T helper type 2 cell immunity by interleukin-4 and interleukin-13. Pharmacol. Ther. 88:143.
22. Kapp, U., Yeh, W. C., Patterson, B. et al. 1999. IL-13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J. Exp. Med. 189:1939.
23. Skinnider, B. F., Elia, A. J., Gascoyne, R. D. et al. 2001. Interleukin 13 and IL-13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 97:250.
24. Udaychander, M., Meenakshi, A., Muthiah, R. and Sivanandham, R. 1987. Tumor targeting potential of liposomes encapsulating Ga-67 and antibody to Dalton's lymphoma associated antigen (anti-DLAA). Int. J. Radiat. Oncol. Biol. Phys. 13:1713.
25. Kumar, A. and Singh, S. M. 1996. Effect of tumor growth on the blastogenic response of splenocytes: a role of macrophage derived nitric oxide. Immunol. Invest. 25:413.
26. Parajuli, P. and Singh, S. M. 1995. Modulation of hematopoiesis in normal and tumor-bearing mice on in vivo administration of FK565. Int. J. Immunopathol. Pharmacol. 8:103.
27. Parajuli, P. and Singh, S. M. 1996. Alteration in IL-1 and arginase activity of tumor-associated macrophages: a role in the promotion of tumor growth. Cancer Lett. 107:249.
28. Deepak, P., Kumar, S. and Acharya, A. 2009. Over expression of interleukin-13 in a murine T-cell lymphoma: a possible factor of DL-induced immunosuppression and tumor progression. Cancer Invest. 27:641.
29. Issekutz, T. B., Stoltz, J. M. and Meide, P. V. D. 1988. Lymphocyte recruitment in delayed-type hypersensitivity. The role of IFN-gamma. J. Immunol. 140:2989.
30. Larsen, C. G., Thomsen, M. K., Gesser, B. et al. 1995. The delayed-type hypersensitivity reaction is dependent on IL-8. Inhibition of a tuberculin skin reaction by an anti-IL-8 monoclonal antibody. J. Immunol. 155:2151.
31. Rand, M. L., Warren, J. S., Mansour, M. K., Newman, W. and Ringler, D. J. 1996. Inhibition of T cell recruitment and cutaneous delayed type hypersensitivity-induced inflammation with anti-bodies to monocyte chemoattractant protein-1. Am. J. Pathol. 148:855.
32. Doyle, H. A. and Murphy, J. W. 1997. MIP-1a contributes to the anticryptococcal delayed-type hypersensitivity reaction and protection against Cryptococcus neoformans. J. Leukoc. Biol. 61:147.
33. Bernhagen, J., Bacher, M., Calandra, T. et al. 1996. An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J. Exp. Med. 183:277.
34. Gautam, S., Battisto, J., Major, J. A., Armstrong, D., Stoler, M. and Hamilton, T. A. 1994. Chemokine expression in trinitrochlorobenzene-mediated contact hypersensitivity. J. Leukoc. Biol. 55:452.
35. Devergne, O., Marfaing-Koka, A., Schall, T. T. et al. 1994. Production of the RANTES chemokine in delayed-type hypersensitivity reactions: involvement of macrophages and endothelial cells. J. Exp. Med. 179:1689.
36. Lathers, D. M. R. and Young, M. R. I. 2004. Increased aberrance of cytokine expression in plasma of patients with more advanced squamous cell carcinoma of the head and neck. Cytokine 25:220.
37. An, B., Goldfarb, R. H., Siman, R. and Dou, Q. P. 1998. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 5:1062.
38. Back, O. and Larsen, A. 1982. Contact sensitivity in mice evaluated by means of ear thickness and a radiometric test. J. Invest. Dermatol. 78:309.
39. Deepak, P., Kumar, S. and Acharya, A. 2007. IL-13 Ra2-mediated interleukin-13 neutralization represses in vivo progressive growth of a T-cell lymphoma. J. Exp. Clin. Cancer Res. 26:347.
40. Skinnider, B. F., Kapp, U. and Mak, T. W. 2002. The role of interleukin 13 in classical Hodgkin lymphoma. Leuk. Lymphoma 43:1203.
41. Skinnider, B. F., Kapp, U. and Mak, T. W. 2001. Interleukin 13: a growth factor in Hodgkin lymphoma. Int. Arch. Allergy Immunol. 126:267.
42. Powrie, F., Menon, S. and Coffman, R. L. 1993. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. Eur. J. Immunol. 23:3043.
43. Mu, H.-H. and Sewell, W. A. 1994. Regulation of DTH and IgE responses by IL-4 and IFN-γ in immunized mice given pertusis toxin. Immunology 83:639.
44. Fong, T. A. and Mosmann, T. R. 1989. The role of IFN-γ in delayed type hypersensitivity mediated by Th1 clones. J. Immunol. 143:2887.
45. Piguet, P. F., Grau, G. E., Hauser, C. and Vaselli, P. 1991. Tumor necrosis factor is a critical mediator in hapten induced irritant and contact hypersensitivity reactions. J. Exp. Med. 173:673.
46. Macedo, M. S., Faquim-Mauro, E., Ferreira, A. P. and Abrahamsohn, I. A. 1998. Immunomodulation induced by Ascaris suum extract in mice. Effect of anti-interleukin-4 and anti-interleukin-10 antibodies. Scan. J. Immunol. 47:10.
47. Jacysyn, J. F., Abrahamsohn, I. A. and Macedo, M. S. 2003. IL-4 from Th2 type cells suppresses induction of delayed type hypersensitivity elicited shortly after immunization. Immunol. Cell Biol. 81:424.
48. Gordon, S. and Taylor, P. R. 2005. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5:953.
49. Deepak, P., Kumar, S. and Acharya, A. 2007. IL-13 neutralization modulates function of type II polarized macrophages in vivo in a murine T-cell lymphoma. Eur. J. Inflammation 5:29.
50. Deepak, P., Kumar, S. and Acharya, A. 2008. Interleukin-13 neutralization modulates interleukin-13 induced suppression of reactive oxygen species production in peritoneal macrophages in a murine T-cell lymphoma. Cell Immunol. 251:72.
51. Biswas, S. K., Sica, A. and Lewis, C. E. 2008. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J. Immunol. 180:2011.
52. Martinez, F. O., Sica, A., Mantovani, A. and Locati, M. 2008. Macrophage activation and polarization. Front. Biosci. 13:453.
53. Minty, A., Chalon, P., Derocq, J.-M. et al. 1993. Interleukin-13 is a new human lymphokine regulatory inflammatory and immune response. Nature 362:248.
54. McKenzie, A. N. J., Culpepper, J. A., de Waal Malefyt, R. et al. 1993. Interleukin-13, a T-cell derived cytokine that regulates human monocytes and B-cell function. Proc. Natl Acad. Sci. USA 90:3735.
55. de Waal Malefyt, R., Figdor, C. G., Huijbens, R. et al. 1993. Effects of IL-13 on phenotype, cytokine production and modulation by IFN-γ or IL-10. J. Immunol. 15:6370.